The glucagon-like peptide-1 analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 5, 2015, Pages 694-702

  Gao, Huiting ^a   Zeng, Zhigang ^a   Zhang, Han ^a   Zhou, Xiaoli ^a   Guan, Lichang ^a   Deng, Weiping ^a   Xu, Lishu ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Adiponectin; Inflammatory response; Liraglutide; Non alcoholic fatty liver disease; Oxidative stress

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; MALONALDEHYDE; STRESS ACTIVATED PROTEIN KINASE 1; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FATTY LIVER; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIVER DYSFUNCTION; LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG EFFECTS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; SPRAGUE DAWLEY RAT;

ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIRAGLUTIDE; LIVER; MALE; MALONDIALDEHYDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929460983     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00505     Document Type: Article

References (59)

1. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes. Metab., 13, 692-702 (2011).
2. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U.S.A., 106, 15430-15435 (2009).
3. Baffy G. Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention. Journal of Clinical and Translational Hepatology, 1, 131-137 (2013).
4. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int., 30, 795-808 (2010).
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 43 (Suppl. 1), S99-S112 (2006).
6. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis., 42, 320-330 (2010).
7. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve. Clin. J. Med., 75, 721-728 (2008).
8. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology, 114, 842-845 (1998).
9. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 42, 987-1000 (2005).
10. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 35, 373-379 (2002).
11. Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin. Liver Dis., 16, 631-645 (2012).
12. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology, 38, 413-419 (2003).
13. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut, 53, 413-419 (2004).
14. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev., 60, 470-512 (2008).
15. Lee J, Hong SW, Rhee EJ, Lee WY. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab. J., 36, 262-267 (2012).
16. Kim YO, Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am. J. Physiol. Gastrointest. Liver Physiol., 302, G759-G761 (2012).
17. Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am. J. Physiol. Endocrinol. Metab., 302, E334-E343 (2012).
18. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, Ha SY, Kang Y, Kim Y, Jun HS. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia, 55, 2456-2468 (2012).
19. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis, 221, 375-382 (2012).
20. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis, 232, 156-164 (2014).
21. Okada K, Kotani K, Yagyu H, Ando A, Osuga JI, Ishibashi S. Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine, 47, 962-964 (2014).
22. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation, 127, 74-85 (2013).
23. Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur. J. Pharmacol., 700, 42-50 (2013).
24. Gao H, Xu L, Li D, Guang L, Deng W. Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Xue Bao, 33, 1661-1664 (2013).
25. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes. Metab., 12, 365-383 (2010).
26. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med., 9, 299-314 (2009).
27. Chen SJ, Yen CH, Huang YC, Lee BJ, Hsia S, Lin PT. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS ONE, 7, e45693 (2012).
28. Zhang L, Yang M, Ren H, Hu H, Boden G, Li L, Yang G. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int., 33, 794-804 (2013).
29. Tan Y, Zhang JN, Chen JH, Wang LJ, Liu HX. Role of JNK signal transduction pathway in nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi, 17, 821-825 (2009).
30. Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatory pathway. Curr. Opin. Investig. Drugs, 6, 979-987 (2005).
31. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Osterreicher CH, Schnabl B, Seki E, Brenner DA. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology, 137, 1467-1477 e5 (2009).
32. Wu N, Lu Y, He B, Zhang Y, Lin J, Zhao S, Zhang W, Li Y, Han P. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo. Diabetes Res. Clin. Pract., 90, 288-296 (2010).
33. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature, 420, 333-336 (2002).
34. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem., 226, 497-509 (1957).
35. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic. Biol. Med., 31, 331-335 (2001).
36. Tinnikov AA, Boonstra R. Colorimetric micro-determination of free fatty acids in plasma using microplate readers. Clin. Chim. Acta, 281, 159-162 (1999).
37. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem., 47, 469-474 (1974).
38. Jain SK, Micinski D, Lieblong BJ, Stapleton T. Relationship between hydrogen sulfide levels and HDL-cholesterol, adiponectin, and potassium levels in the blood of healthy subjects. Atherosclerosis, 225, 242-245 (2012).
39. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 405, 458-462 (2000).
40. Hunt GB, Luff JA, Daniel L, Van den Bergh R. Evaluation of hepatic steatosis in dogs with congenital portosystemic shunts using Oil Red O staining. Vet. Pathol., 50, 1109-1115 (2013).
41. Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem. Biophys. Res. Commun., 338, 668-676 (2005).
42. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes. Rev., 5, 27-42 (2004).
43. Vickers AE. Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. Toxicol. Pathol., 37, 78-88 (2009).
44. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch. Physiol. Biochem., 114, 183-194 (2008).
45. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine, 23, 177-182 (2004).
46. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med., 33, 337-349 (2002).
47. Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J. Appl. Toxicol., 29, 69-78 (2009).
48. Jung JH, Kim HS. The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat dietinduced non-alcoholic fatty liver disease. Food Chem. Toxicol., 60, 404-412 (2013).
49. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol., 305, H295-H304 (2013).
50. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int., 31, 1285-1297 (2011).
51. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N. Engl. J. Med., 362, 774-777 (2010).
52. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE, 6, e25269 (2011).
53. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 43, 173-181 (2006).
54. Méndez-Sánchez N, Chávez-Tapia NC, Villa AR, Sánchez-Lara K, Zamora-Valdés D, Ramos MH, Uribe M. Adiponectin as a protective factor in hepatic steatosis. World J. Gastroenterol., 11, 1737-1741 (2005).
55. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism, 60, 313-326 (2011).
56. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J. Genet. Genomics, 35, 321-326 (2008).
57. He M, Su H, Gao W, Johansson SM, Liu Q, Wu X, Liao J, Young AA, Bartfai T, Wang MW. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS ONE, 5, e14205 (2010).
58. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw-Boris A, Scadeng M, Olefsky JM, Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab., 6, 386-397 (2007).
59. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc. Drugs Ther., 27, 371-380 (2013).